Abbonarsi

EUS-guided antegrade intervention for benign biliary diseases in patients with surgically altered anatomy (with videos) - 21/01/19

Doi : 10.1016/j.gie.2018.07.030 
Shuntaro Mukai, MD 1, Takao Itoi, MD, FASGE 1, , Atsushi Sofuni, MD 1, Takayoshi Tsuchiya, MD 1, Reina Tanaka, MD 1, Ryosuke Tonozuka, MD 1, Mitsuyoshi Honjo, MD 1, Mitsuru Fujita, MD 1, Kenjiro Yamamoto, MD 1, Yuichi Nagakawa, MD 2
1 Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan 
2 Third Department of Surgery, Tokyo Medical University, Tokyo, Japan 

Reprint requests: Takao Itoi, MD, PhD, FACG, FASGE, Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan.Department of Gastroenterology and HepatologyTokyo Medical University6-7-1 NishishinjukuShinjuku-kuTokyo160-0023Japan

Abstract

Background and Aims

Although balloon enteroscopy–assisted ERCP (BE-ERCP) is effective and safe for benign biliary diseases in patients with surgically altered anatomy (SAA), BE-ERCP is not always successful. Recently, EUS-guided antegrade intervention (EUS-AI) by using a 1-stage or 2-stage procedure has been developed for BE-ERCP failure cases. The aim of the present study was to evaluate the outcome of EUS-AI for benign biliary diseases in patients with SAA.

Methods

Of 48 patients in whom BE-ERCP failed, percutaneous transhepatic intervention was performed in 11. From November 2013 until November 2017, we retrospectively reviewed cases of an additional 37 patients with SAA who failed BE-ERCP and underwent EUS-AI for benign biliary diseases (common bile duct stones [n = 11], intrahepatic bile duct stones [n = 5], anastomotic strictures [n = 21]).

Results

The overall technical success of the creation of the hepatoenteric tract by EUS was 91.9% (34/37). Moderate adverse events were observed in 8.1% (biliary peritonitis [n = 3]). One-stage EUS-AI by EUS succeeded in 8 cases (100%) without any adverse events. In another 26 cases, 2-stage EUS-AI by ERCP was performed about 1 or 2 months later. Endoscopic antegrade therapy under fluoroscopy was successful in 6 cases. Per-oral cholangioscopy–assisted antegrade intervention was required in 19 cases (guidewire manipulation across the anastomotic stricture [n = 6], cholangioscopy-guided lithotripsy by using electrohydraulic lithotripsy [n = 13]). In 1 case, magnetic compression anastomosis was performed. The final clinical success rate of all EUS-AIs was 91.9%.

Conclusions

EUS-AI for benign biliary diseases in patients with SAA appears to be a feasible and safe alternative procedure after BE-ERCP failure.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : BE-ERCP, EUS-AI, EUS-BD, EUS-HGS, EUS-HJS, MS, PCSEMS, POCS-AI, SAA


Mappa


 DISCLOSURE: T. Itoi is a speaker for Boston Scientific Japan and Olympus Medical System. All other authors disclosed no financial relationships relevant to this publication.
 If you would like to chat with an author of this publication, you may contact Dr Itoi at itoi@tokyo-med.ac.jp.


© 2019  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 89 - N° 2

P. 399-407 - febbraio 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer
  • John M. DeWitt, Kumar Sandrasegaran, Bert O'Neil, Michael G. House, Nicholas J. Zyromski, Amikar Sehdev, Susan M. Perkins, Janet Flynn, Lynne McCranor, Safi Shahda
| Articolo seguente Articolo seguente
  • Fully automated diagnostic system with artificial intelligence using endocytoscopy to identify the presence of histologic inflammation associated with ulcerative colitis (with video)
  • Yasuharu Maeda, Shin-ei Kudo, Yuichi Mori, Masashi Misawa, Noriyuki Ogata, Seiko Sasanuma, Kunihiko Wakamura, Masahiro Oda, Kensaku Mori, Kazuo Ohtsuka

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.